110 results on '"Goyal, Namita A."'
Search Results
2. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial
3. Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes
4. Misdiagnosis of amyotrophic lateral sclerosis in clinical practice in Europe and the USA: a patient chart review and physician survey
5. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
6. A Hemizygous Deletion Within the PGK1 Gene in Males with PGK1 Deficiency
7. Inclusion Body Myositis
8. Imaging beyond muscle magnetic resonance imaging in inclusion body myositis
9. Trial of Intravenous Immune Globulin in Dermatomyositis
10. Correlations of disease severity outcome measures in inclusion body myositis
11. Current status of clinical outcome measures in inclusion body myositis: a systematised review
12. Oculopharyngeal muscular dystrophy
13. FACE MASK, ROAD TRAFFIC AND LICENSE PLATE DETECTION USING YOLOv3
14. FACE MASK, ROAD TRAFFIC AND LICENSE PLATE DETECTION USING YOLOv3
15. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial
16. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of the Efficacy and Safety of Losmapimod in Subjects with FSHD: ReDUX4 (S23.007)
17. Reachable Workspace to Evaluate Efficacy of Losmapimod in Subjects with FSHD in Two Phase 2 Studies (P4-13.008)
18. CSF biomarkers evaluated by principal component analysis in a NurOwn Phase 3 clinical trial (P1-1.Virtual)
19. Safety and Tolerability of SARS-Cov-2 Vaccination in Patients with Neuromuscular Disorders: A Single Center Experience (P11-13.003)
20. Whole Body MRI Quantitative muscle analysis to evaluate Efficacy of Losmapimod in a Phase 2 Placebo-Controlled Study in Subjects with FSHD (ReDUX4) (S23.009)
21. CYTODIAGNOSIS OF SCAR ENDOMETRIOSIS- A SERIES OF 3 CASES WITH REVIEW OF LITERATURE
22. Immunophenotyping of Inclusion Body Myositis Blood T and NK Cells
23. A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis
24. MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design
25. Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices
26. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial
27. QUANTITATIVE ANALYSIS OF BIOCHEMICALAND HEMATOLOGICAL MARKERS IN COVID 19 PATIENTS AT DEDICATED COVID CARE HOSPITAL IN SOUTHERN RAJASTHAN
28. Single breath counting is an effective screening tool for forced vital capacity in ALS
29. Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
30. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
31. Inflammatory Myopathies
32. CORONA CASE PREDICTOR
33. Clinical Correlates of Blood KLRG1+ T cells in Inclusion Body Myositis (2802)
34. Neuromuscular Clinician Preferences and Experience in the Management of Myasthenic Crisis (2662)
35. Anti-signal recognition particle (Anti-SRP) autoantibody myopathy presenting with profound scapular winging and lumbar lordosis: an uncommon presentation (2573)
36. A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis
37. AB016. A double-blind, placebo-controlled, phase 2 trial of a novel toll-like receptor 7/8/9 antagonist (IMO-8400) in dermatomyositis
38. Clinical utility of anti‐cytosolic 5’‐nucleotidase 1A antibody in idiopathic inflammatory myopathies
39. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis
40. Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis
41. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS
42. Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
43. Attitudes Toward Noninterventional Observational Studies in US and Australian Patients With Sporadic Inclusion Body Myositis
44. Clinical Correlates of Variant KLRG1-expressing T cells in Inclusion Body Myositis (2466)
45. Validation of the Spanish Version of the 15-Item Myasthenia Gravis Quality of Life Scale (MG-QOL15) (1122)
46. Effects of Mexiletine on Cortical and Peripheral Nerve Hyperexcitability in Sporadic ALS (2531)
47. Survey to assess variability in management of myasthenic crisis among neurologists (4103)
48. Design of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD): ReDUX4 (1592)
49. Myositis associated anti-NT5C1A autoantibody in clinical practice
50. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.